About BioServe

BioServe's Global BioRepository provides leading academic and industry researchers with access to over 600,000 human DNA, tissue and serum samples linked to detailed clinical and demographic data from 120,000 consented and anonymized patients on four continents.

Utilizing BioServe's preclinical molecular services, researchers can identify genetic markers, validate drug targets and correlate clinical and molecular data to accelerate the development of new and safer drugs.

BioServe's customers include nearly every major pharmaceutical and biotechnology company, as well as top industry, academic, and government research institutions.

Founded in 1989, BioServe has corporate headquarters in Beltsville, Maryland and Hyderabad, India.

How we got here

2010 BioServe Europe founded in August Formed BioServe Network

2009 Upgraded current facility laboratory space to current 21,000 square feet footprint

2007 Acquired assets of Genomics Collaborative, Inc. from SeraCare Obtained CLIA certification Relocated to current facility in Beltsville, Maryland

2006 Expanded high-throughput genotyping capabilities with iPlex platform from Sequenom BioServe India relocates to expanded laboratory facility (14,000 sq. ft.)

2003 Acquired assets of Qiagenomics in Seattle, Washington

2002 BioServe India founded in Hyderabad, India

2001 Renewal of NIEHS contract for an additional 5 years Integrated high-throughput genotyping capabilities into services (Sequenom)

2000 BioServe presents three abstracts and one oral mini-symposium on p53 at annual meeting of American Association for Cancer Research (AACR) in Philadelphia

1998 BioServe integrates real-time PCR platform into services line (ABI)

1997 BioServe upgrades to high-throughput DNA synthesizer platforms

1996 BioServe expands laboratory space from 5,000 square feet to 12,000 square feet in Laurel facility

1995 BioServe secures first multi-year contract with National Institutes of Environmental Health Sciences (NIEHS)

1994 BioServe obtains three SBIR grants for fingerprinting in breast and prostate cancer, as well as detection of RAS mutations using LCR

1993 BioServe secures first Small Business Innovation Research (SBIR) grant for sub-typing HPV in oral cancers

1992 BioServe graduates from TAP and re-locates to facility in Laurel, Maryland

1991 BioServe secures first blanket purchase order agreement with NIH

1990 January 5 - BioServe officially incorporated as a business

1989 October 7 -BioServe founded by researchers who left National Cancer Institute with funding from the University of Maryland Technology Advancement Program (TAP)